Efficacy of calcineurin inhibitors in interstitial lung disease of patients with antisynthetase syndrome: a systematic literature review and single-arm prevalence meta-analysis
Authors' conclusion
CNIs, in combination with glucocorticoids, can be effective for treating acute/subacute and chronic ILD in patients with ASyS. However, relapses of ILD can frequently occur under this treatment modality.
Study context
- Population
- Patients with interstitial lung disease (ILD) associated with antisynthetase syndrome (ASyS)12 studies
- Outcome
- Overall efficacy of CNIs (improvement and stable disease) in ASyS-ILD
Methodological detailsproportions as effect sizes, Cochrane Reviews, MEDLINE, Ovid, Scopus, and Web of Science searched
- Proportions as effect sizes
- Cochrane Reviews, MEDLINE, Ovid, Scopus, and Web of Science searched
Pooled result
As reported in the abstract
Improvement and stable disease, overall ASyS-ILD
Calcineurin inhibitors (CNIs)
88.4 %
95% CI 78.2–95.7
Further pooled results
| Outcome | Values |
|---|---|
| Improvement and stable disease, acute/subacute ASyS-ILD | CNIs 91.5 % (95% CI 65.5–99.9) |
| Improvement and stable disease, chronic ASyS-ILD | CNIs 84.9 % (95% CI 64.0–97.6) |
Safety
| Outcome | Values |
|---|---|
| ILD relapse under CNI treatment | CNIs 56.4 % (95% CI 47.9–65.2) |
Original publication
Efficacy of calcineurin inhibitors in interstitial lung disease of patients with antisynthetase syndrome: a systematic literature review and single-arm prevalence meta-analysis. Clin Exp Rheumatol. Published 26 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →